Almiral launches Seysara tablets in the U.S. for treatment of common acne patients

recently, Spain's Almiralcompany(http:// announcedthe launch of Seysara tablets in the United States for treatment of patients with moderate to severe non-nodactive inflammatory acne at age 9 and olderin the United States, Seysara was approved in early October 2018, becoming the first oral antibioticproduct designed for dermatology in the past 40 years,(http://, which will provide an innovative treatment option for patients with moderate to severe acneabout Seysara
Seysara is a pioneering (first-in-class), narrow-spectrum tetracycline-derived antibiotic, which has anti-inflammatory properties and is taken daily orally, can be taken with or without food, and has been shown in clinical studies to achieve a statistically significant improvement in dermatital lesions within 3 weeks of starting the drug, with good safety and toleranceSeysara was discovered by the antibiotic company Paratek and granted the exclusive rights to the product to Aer Insp, while retaining the rights to develop and commercialize the product in other parts of the worldin early August, Almirall announced a $550 million acquisition of five products from the http://dermatology division of El-Sin in the United
States, including four mature brands, Aczone ®, T®aztenaroe, Azelex® and Cordrasan®, as well as the first-of-its-kind innovative four-ring-derived antibiotic, SeysaraUnder the previous agreement between Paratek and ElJian, This time Seysara was approved by the u.SFDA(http:// , Paratek will receive a $12 million milestone and be entitled to tiered royalties related to Seysara's net sales in the U.S market safety it is important to note that the Seysara taboo is used in patients with allergies to the http:// of the drug , which can cause permanent discoloration during dental development Seysara should be deactivated in the event of clottalysis-associated diarrhea (antibiotic-related colitis) or intracranial hypertension Central nervous system side effects, the most common including mild dizziness or dizziness, have been reported in tetracycline therapy In clinical studies, the most common adverse reactions of Seysara (incidence of 1%) were nausea